A 4‐week concurrent treatment with GW9662 markedly mitigated the BBR‐mediated exacerbation of hepatic steatosis and liver injury in db/db mice as indicated by a substantial reduction in liver weight and size (Figure 7B–F), as well as a notable decline in serum levels of ALT, AST, and creatinine (Figure 7G–I). This evidence concerns the gene GPT and fatty liver disease.